Mental health often has a cost that isn’t revealed on a balance sheet. Depression, anxiety, and OCD often debilitate people and prevent them from leading a purposeful life. Dr. Matthew Zuch, a licensed clinical psychologist, points to a reality where many patients are often trapped in cycles of persistent symptoms despite medication and psychotherapy.
He believes that while mental health awareness exists, treatments, until recently, have not kept pace. According to him, the gap between awareness and effective intervention reflects a larger issue within psychiatry itself, and that issue lies in technology, or its lack thereof.
“Traditionally, when you talk technology for a psychologist or a psychiatrist, you’re talking about a pad, a pencil, and a couch,” he says. “For most of its history, the field has been remarkably, even stubbornly, low-tech.” He contrasts this with other specialities of general medicine, where a broken bone or a tumor may be addressed with X-ray machines, MRIs, robot-assisted surgery, or even stem-cell replacements.
“Every imaginable type of technology is working for medicine. But for some reason, mental health has been left behind,” he states.
Dr. Zuch, clinical director of NeuroBoost, recently expanded the clinic’s presence in Bloomfield, New Jersey, with a new location focused on Transcranial Magnetic Stimulation (TMS). The FDA-approved treatment, he notes, uses targeted magnetic pulses to stimulate specific neural circuits associated with mood regulation and cognitive processing. NeuroBoost specializes in treatment-resistant depression, anxiety, ADHD, and obsessive-compulsive disorder (OCD), particularly among patients who have already tried several interventions without sufficient relief.
Mental health, Dr. Zuch believes, has long been the stepchild of the medical field, under-resourced and under-innovated. Major Depressive Disorder ranks 13th globally as the cause of disability and mortality, with 75% recurrence rate. He argues that psychiatry has historically relied on comparatively limited treatment tools. He points to current psychiatric medications, noting that they do represent genuine scientific progress. However, he notes that they work only on neurotransmitters, not on the neurons themselves.
TMS, in that context, represents both an exciting new technology and a new treatment pathway working on neurons. Studies show that nearly 80% of patients experience meaningful symptom reduction, while some achieve remission after treatment. “The treatment applies a high-intensity magnetic pulse near the dorsolateral prefrontal cortex, which is a brain region associated with mood regulation and executive function,” he explains. Instead of delivering direct electrical current through the skull, which can lead to significant side effects, he highlights that the magnetic field induces electrical activity within targeted neural circuits, which has a low side effect profile.
Crucially, what the magnetic field does, according to Dr. Zuch, is stimulate neuroplasticity. That is the brain’s capacity to prune maladaptive neural pathways associated with chronic depression, anxiety, or OCD and establish new ones. “When we’re kids, we have a lot of neuroplasticity, but as we grow older, that diminishes. TMS aims to boost that,” he explains.
Dr. Zuch describes the treatment as non-invasive and outpatient-based, requiring no anesthesia or surgical implantation. Sessions, he adds, generally last about 20 minutes, with roughly 30 sessions administered four or five times weekly over a course of six weeks, or 6 times daily over a course of five days.
He often works with individuals whose symptoms have disrupted careers, relationships, and daily functioning. Some, he notes, struggle to leave their homes, while others may lose confidence in their ability to return to work or maintain routines that once felt very manageable.
“There are really three treatment pathways. Talk therapy works on the psyche, pharmacotherapy acts on the neurotransmitter systems to modulate affect, and TMS targets the neurons themselves,” he says. “The strongest outcomes are attained when all three pathways are engaged in cohesion.”
He insists that patients dealing with severe depression, anxiety, or OCD require strong support systems to challenge distorted thought patterns and regain confidence in daily functioning.
The human brain, he notes, contains immense complexity, making psychiatric treatment far more nuanced than treating tangible illnesses. Within that context, he believes technological innovation is becoming essential as clinicians search for more precise and effective interventions.
Still, he chooses not to let the technology become the full story. Because after all is said and done, there is still a person, someone who has spent months or years struggling to get out of bed, to hold a career together, to build relationships, to believe that things could be otherwise. That perspective, he posits, has to be the focal point. TMS may improve symptom burden, but recovery ultimately centers on helping patients reconnect with ordinary life.
He remarks, “We can use all the technology in the world, but the best breakthroughs usually happen when someone believes that feeling better is actually possible.”